FDA approved Pfizer-BioNTech’s XFG-adapted COMIRNATY formula for adults 65 and older and high-risk people aged 5 to 64 years.
News|Articles|October 17, 2022
The Daily Dose: Adult RSV Vaccine
Author(s)Sydney Jennings
Advertisement
Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study.
The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.
On October 14, 2022, we reviewed a pivotal phase 3 clinical trial of an investigational respiratory syncytial virus (RSV) vaccine (RSVPreF3 OA) for older adults.
The study
The phase 3 randomized placebo-controlled AReSVi-006 trial enrolled 25 000 participants from 17 countries to evaluate efficacy of a single dose of the adjuvanted RSVPreF3 OA investigational vaccine in adults aged ≥60 years. Findings, which will be presented at IDWeek 2002 later this month, showed overall vaccine efficacy of 82.6% against RSV-lower respiratory tract disease, satisfying the trial’s primary endpoint.
A note from the manufacturer
“These are truly exceptional results given that today RSV remains one of the major infectious diseases without a vaccine, despite over 60 years of research,” said GSK chief scientific officer Tony Wood in a statement.
The company believes that these robust findings suggest the potential for RSVPreF3 OA to help reduce the global burden of RSV-LRTD, and particularly among older and the most vulnerable adults.
Click here for the full study review.
Advertisement
Related to this article
A Vaccine Integrity Project review found influenza, COVID-19, and RSV immunizations continue to protect against severe illness, hospitalization, and death.
FDA approved bictegravir/lenacapavir for adults with suppressed HIV-1 and no known or suspected component resistance.
FDA expands dolutegravir dispersible tablets to children with HIV-1 weighing at least 2 kg, including eligible term newborns.
Pre-existing antibodies to common microbes predicted COVID-19 vaccine response strength in healthy and immunosuppressed adults.
The organizations challenge a presidential executive order narrowing routine childhood vaccine recommendations and urging vaccines to be given separately.
FDA acceptance starts review of clesrovimab for second-season RSV prevention in high-risk children younger than 2 years.
Endocrine Society statement highlights key research gaps on obesity drugs—who benefits, long-term dosing, safety, and measuring success beyond weight loss.
Advertisement
Advertisement
Trending on Patient Care Online
1
ASH Raises Ferritin Thresholds for Diagnosing Iron Deficiency
2
Combating Prostate Cancer Misconceptions in Primary Care: An Expert Discussion
3
The Shift From Off-Label Use to On-Label Agitation Therapy
4
Endocrine Society Obesity Statement Calls for Goals Beyond Weight Loss
5